Srilatha Reddy, MD
Family Medicine · Irving, TXNPI 1942415930
Payments from drug & device makers
Across 145 payments — averaging $22.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$597
- GSK$500
- Bayer$455
- AstraZeneca$418
- Boehringer Ingelheim$306
- Amarin Pharma, Inc.$194
- plus $745 from 19 others
What the payments were for
- Food & beverage$3,215100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $597 |
| GSK | 16 | $500 |
| Bayer | 8 | $455 |
| AstraZeneca | 23 | $418 |
| Boehringer Ingelheim | 15 | $306 |
| Amarin Pharma, Inc. | 9 | $194 |
| Lilly USA, LLC | 11 | $182 |
| Pfizer | 5 | $91 |
| Merck | 5 | $77 |
| Astellas Pharma US Inc | 3 | $54 |
| Abbott | 2 | $38 |
| Amgen | 2 | $35 |
| Galderma Laboratories, L.p. | 1 | $32 |
| Novartis | 1 | $26 |
| AbbVie | 1 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Merz North America, Inc. | 1 | $23 |
| Renalytix AI, Inc. | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Celltrion USA Inc. | 1 | $21 |
| Boston Scientific | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Echosens North America, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$375
- TRELEGY ELLIPTA$226
- Tresiba$113
How this compares
$3,215 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 43 | $70,133 |
| OzempicSemaglutide | 39 | $62,896 |
| JanuviaSitagliptin Phosphate | 25 | $43,556 |
| EliquisApixaban | 42 | $39,648 |
| JardianceEmpagliflozin | 24 | $32,503 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $26,092 |
| MounjaroTirzepatide | 21 | $22,564 |
| ProliaDenosumab | 12 | $21,223 |
| VascepaIcosapent Ethyl | 22 | $17,694 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $16,637 |
| MyrbetriqMirabegron | 11 | $12,933 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $10,135 |
| Pro Comfort Alcohol PadsAlcohol Antiseptic Pads | 37 | $3,983 |
| Comfort Touch Pen NeedlePen Needle, Diabetic | 14 | $2,780 |
| Rosuvastatin Calcium | 216 | $2,135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $418 | $80,26856 claims |
| Novo NordiskOzempic | $597 | $62,89639 claims |
| MerckJanuvia, Janumet Xr | $77 | $60,19336 claims |
| PfizerEliquis | $91 | $39,64842 claims |
| Boehringer IngelheimJardiance | $306 | $32,50324 claims |
| GSKTrelegy Ellipta | $500 | $26,09220 claims |
| Lilly USA, LLCMounjaro | $182 | $22,56421 claims |
| AmgenProlia | $35 | $21,22312 claims |
| Astellas Pharma US IncMyrbetriq | $54 | $12,93311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Irving
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.